Non-linear dose response of lymphocyte cell lines to microtubule inhibitors

Daria M. Potashnikova, E. Aleena A. Saidova, Anna V. Tvorogova, Eugene V. Sheval, Ivan Vorobyev

Research output: Contribution to journalArticle

Abstract

Microtubule (MT) inhibitors show anti-cancer activity in a wide range of tumors in vitro and demonstrate high clinical efficacy. To date they are routinely included into many chemotherapeutic regimens. While the mechanisms of MT inhibitors' interactions with tubulin have been well-established, the relationship between their concentration and effect on neoplastic cells is not completely understood. The common notion is that tumor cells are most vulnerable during division and all MT inhibitors block them in mitosis and induce mitotic checkpoint-associated cell death. At the same time multiple evidence of more subtle effects of lower doses of MT inhibitors on cell physiology exist. The extent of efficacy of the low-dose MT inhibitor treatment and the mechanisms of resulting cell death currently present a critical issue in oncology. The prospect of MT inhibitor dose reduction is promising as protocols at higher concentration have multiple side effects. We assessed cell cycle changes and cell death induced by MT inhibitors (paclitaxel, nocodazole, and vinorelbine) on human lymphoid B-cell lines in a broad concentration range. All inhibitors had similar accumulation effects and demonstrated "trigger" concentrations that induce cell accumulation in G2/M phase. Concentrations slightly below the "trigger" promoted cell accumulation in sub-G1 phase. Multi-label analysis of live cells showed that the sub-G1 population is heterogeneous and may include cells that are still viable after 24 h of treatment. Effects observed were similar for cells expressing Tatprotein. Thus cell cycle progression and cell death are differentially affected by high and low MT inhibitor concentrations.

Original languageEnglish
Article number436
JournalFrontiers in Pharmacology
Volume10
Issue numberAPR
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Microtubules
Lymphocytes
Cell Line
Cell Death
Cell Cycle
M Phase Cell Cycle Checkpoints
Nocodazole
Cell Physiological Phenomena
Neoplasms
G2 Phase
G1 Phase
Tubulin
Paclitaxel
Mitosis
Cell Division
B-Lymphocytes
Population

Keywords

  • B-lymphocytes
  • Cell cycle
  • Cell death
  • Microtubule inhibitors
  • Nocodazole
  • Paclitaxel
  • RPMI8866
  • Vinorelbine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Non-linear dose response of lymphocyte cell lines to microtubule inhibitors. / Potashnikova, Daria M.; Saidova, E. Aleena A.; Tvorogova, Anna V.; Sheval, Eugene V.; Vorobyev, Ivan.

In: Frontiers in Pharmacology, Vol. 10, No. APR, 436, 01.01.2019.

Research output: Contribution to journalArticle

Potashnikova, Daria M. ; Saidova, E. Aleena A. ; Tvorogova, Anna V. ; Sheval, Eugene V. ; Vorobyev, Ivan. / Non-linear dose response of lymphocyte cell lines to microtubule inhibitors. In: Frontiers in Pharmacology. 2019 ; Vol. 10, No. APR.
@article{6cd7b8bdb8e94841acf8a089201ff26e,
title = "Non-linear dose response of lymphocyte cell lines to microtubule inhibitors",
abstract = "Microtubule (MT) inhibitors show anti-cancer activity in a wide range of tumors in vitro and demonstrate high clinical efficacy. To date they are routinely included into many chemotherapeutic regimens. While the mechanisms of MT inhibitors' interactions with tubulin have been well-established, the relationship between their concentration and effect on neoplastic cells is not completely understood. The common notion is that tumor cells are most vulnerable during division and all MT inhibitors block them in mitosis and induce mitotic checkpoint-associated cell death. At the same time multiple evidence of more subtle effects of lower doses of MT inhibitors on cell physiology exist. The extent of efficacy of the low-dose MT inhibitor treatment and the mechanisms of resulting cell death currently present a critical issue in oncology. The prospect of MT inhibitor dose reduction is promising as protocols at higher concentration have multiple side effects. We assessed cell cycle changes and cell death induced by MT inhibitors (paclitaxel, nocodazole, and vinorelbine) on human lymphoid B-cell lines in a broad concentration range. All inhibitors had similar accumulation effects and demonstrated {"}trigger{"} concentrations that induce cell accumulation in G2/M phase. Concentrations slightly below the {"}trigger{"} promoted cell accumulation in sub-G1 phase. Multi-label analysis of live cells showed that the sub-G1 population is heterogeneous and may include cells that are still viable after 24 h of treatment. Effects observed were similar for cells expressing Tatprotein. Thus cell cycle progression and cell death are differentially affected by high and low MT inhibitor concentrations.",
keywords = "B-lymphocytes, Cell cycle, Cell death, Microtubule inhibitors, Nocodazole, Paclitaxel, RPMI8866, Vinorelbine",
author = "Potashnikova, {Daria M.} and Saidova, {E. Aleena A.} and Tvorogova, {Anna V.} and Sheval, {Eugene V.} and Ivan Vorobyev",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00436",
language = "English",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Non-linear dose response of lymphocyte cell lines to microtubule inhibitors

AU - Potashnikova, Daria M.

AU - Saidova, E. Aleena A.

AU - Tvorogova, Anna V.

AU - Sheval, Eugene V.

AU - Vorobyev, Ivan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Microtubule (MT) inhibitors show anti-cancer activity in a wide range of tumors in vitro and demonstrate high clinical efficacy. To date they are routinely included into many chemotherapeutic regimens. While the mechanisms of MT inhibitors' interactions with tubulin have been well-established, the relationship between their concentration and effect on neoplastic cells is not completely understood. The common notion is that tumor cells are most vulnerable during division and all MT inhibitors block them in mitosis and induce mitotic checkpoint-associated cell death. At the same time multiple evidence of more subtle effects of lower doses of MT inhibitors on cell physiology exist. The extent of efficacy of the low-dose MT inhibitor treatment and the mechanisms of resulting cell death currently present a critical issue in oncology. The prospect of MT inhibitor dose reduction is promising as protocols at higher concentration have multiple side effects. We assessed cell cycle changes and cell death induced by MT inhibitors (paclitaxel, nocodazole, and vinorelbine) on human lymphoid B-cell lines in a broad concentration range. All inhibitors had similar accumulation effects and demonstrated "trigger" concentrations that induce cell accumulation in G2/M phase. Concentrations slightly below the "trigger" promoted cell accumulation in sub-G1 phase. Multi-label analysis of live cells showed that the sub-G1 population is heterogeneous and may include cells that are still viable after 24 h of treatment. Effects observed were similar for cells expressing Tatprotein. Thus cell cycle progression and cell death are differentially affected by high and low MT inhibitor concentrations.

AB - Microtubule (MT) inhibitors show anti-cancer activity in a wide range of tumors in vitro and demonstrate high clinical efficacy. To date they are routinely included into many chemotherapeutic regimens. While the mechanisms of MT inhibitors' interactions with tubulin have been well-established, the relationship between their concentration and effect on neoplastic cells is not completely understood. The common notion is that tumor cells are most vulnerable during division and all MT inhibitors block them in mitosis and induce mitotic checkpoint-associated cell death. At the same time multiple evidence of more subtle effects of lower doses of MT inhibitors on cell physiology exist. The extent of efficacy of the low-dose MT inhibitor treatment and the mechanisms of resulting cell death currently present a critical issue in oncology. The prospect of MT inhibitor dose reduction is promising as protocols at higher concentration have multiple side effects. We assessed cell cycle changes and cell death induced by MT inhibitors (paclitaxel, nocodazole, and vinorelbine) on human lymphoid B-cell lines in a broad concentration range. All inhibitors had similar accumulation effects and demonstrated "trigger" concentrations that induce cell accumulation in G2/M phase. Concentrations slightly below the "trigger" promoted cell accumulation in sub-G1 phase. Multi-label analysis of live cells showed that the sub-G1 population is heterogeneous and may include cells that are still viable after 24 h of treatment. Effects observed were similar for cells expressing Tatprotein. Thus cell cycle progression and cell death are differentially affected by high and low MT inhibitor concentrations.

KW - B-lymphocytes

KW - Cell cycle

KW - Cell death

KW - Microtubule inhibitors

KW - Nocodazole

KW - Paclitaxel

KW - RPMI8866

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=85068487123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068487123&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00436

DO - 10.3389/fphar.2019.00436

M3 - Article

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - APR

M1 - 436

ER -